Venofer Shortage: What Providers and Prescribers Need to Know in 2026

The June–November 2024 Venofer allocation was a critical stress test for nephrology practices, dialysis chains, and outpatient infusion programs across the United States. For the first time in its 25-year history, American Regent's iron sucrose product was placed on restricted allocation — forcing clinicians to rapidly adapt formularies, communicate with patients, and navigate insurance requirements for alternatives.

As of 2026, Venofer supply has been restored to normal levels. However, providers should understand what happened, develop contingency protocols, and be prepared to act quickly if another supply disruption occurs. This guide covers the clinical essentials every prescriber and practice manager should know.

2024 Shortage Timeline and Current Status

June 2024: American Regent placed Venofer on allocation; weekly shipping continued with per-facility order limits

June–November 2024: Constrained supply created real shortfalls at many dialysis centers and infusion suites; facilities with large patient populations were hardest hit

November 2024: Allocation lifted; supply returned to normal levels

2026 status: No active nationwide shortage; Venofer is available through normal distribution channels

Clinical Impact of Iron Sucrose Supply Disruptions

For nephrologists managing CKD patients on erythropoiesis-stimulating agents (ESAs), iron sucrose is not merely a supportive therapy — it's a prerequisite for ESA efficacy. KDIGO guidelines recommend maintaining transferrin saturation (TSAT) ≥20% and serum ferritin ≥200 ng/mL in hemodialysis patients receiving ESA therapy. Iron deficiency impairs ESA response, leading to higher required doses, increased costs, and worse patient outcomes.

During the 2024 shortage, practices reported: increased ESA dose requirements, declining hemoglobin levels in affected patients, increased physician time spent navigating prior authorizations for alternative IV iron products, and heightened patient anxiety. Providers who had pre-established formulary substitution protocols weathered the shortage more effectively.

Formulary Substitution: Clinical Considerations

When Venofer is unavailable, the choice of substitute IV iron should consider indication, dosing logistics, payer requirements, and patient history. Key options:

Generic iron sucrose: Therapeutically equivalent to Venofer per FDA. Same dosing (100–200 mg per session), no prior auth required. First-line substitute.

Ferrlecit (sodium ferric gluconate): Indicated for HDD-CKD patients on ESA therapy. Dose: 125 mg IV per dialysis session; cumulative 1,000 mg over 8 sessions. Generally does not require step therapy authorization.

Feraheme (ferumoxytol): 510 mg IV x2 doses, 3–8 days apart. Indicated for IDA in adults with intolerance/unsatisfactory response to oral iron, or with CKD. Requires prior auth from most private payers, who typically require documented Venofer shortage or intolerance.

Injectafer (ferric carboxymaltose): 750 mg IV x2 doses (≥7 days apart), or 15 mg/kg single dose. Indicated for IDA in adults with NDD-CKD or oral iron intolerance, and for IDA in patients with heart failure (NYHA II/III). Requires prior auth; most appropriate for NDD-CKD patients or when fewer infusion visits are clinically warranted.

Navigating Prior Authorization for Alternative IV Iron

During a supply shortage, obtaining prior authorization for Feraheme or Injectafer can be accelerated by documenting the shortage explicitly. Key elements to include in prior auth requests during a shortage:

Documented inability to obtain Venofer or iron sucrose from current distributor (obtain a written letter or email from your distributor confirming unavailability)

Patient's most recent iron studies (ferritin, TSAT, hemoglobin) demonstrating clinical need

Reference to ASHP or FDA shortage listing if applicable

Request for expedited or peer-to-peer review given clinical urgency

For hemodialysis patients on Medicare Part B, most IV iron products including Feraheme are covered without prior authorization when given during dialysis sessions, which significantly reduces the administrative burden.

39,483+ patients found their medications in stock

39K+

Find Venofer In Stock Today →

Building a Shortage Contingency Protocol

The 2024 shortage highlighted the importance of having a written contingency protocol in place before a crisis occurs. Recommended components:

Identify your formulary substitution hierarchy (e.g., generic iron sucrose → Ferrlecit → Feraheme → Injectafer)

Pre-authorize second-line agents with major payers before a shortage occurs

Establish relationships with backup distributors and specialty pharmacies

Prioritize patients with lowest iron stores when supplies are constrained

Designate a staff member as shortage coordinator to monitor supply levels and communicate proactively with patients

How medfinder Can Support Your Practice

During a shortage, helping patients locate available supply takes significant staff time. medfinder's provider platform can help your practice coordinate patient access to infusion providers that have Venofer or alternative IV iron products in stock. Learn more in our guide to helping your patients find Venofer.